Clinical management of thalassemia. The status of new iron chelators.
D000818:Animals; D002614:Chelating Agents / Q000378:metabolism / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002793:Cholic Acids / Q000494:pharmacology; D003676:Deferoxamine / Q000494:pharmacology; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004758:Enterobactin / Q000031:analogs & derivatives / Q000494:pharmacology; D005029:Ethylenediamines / Q000494:pharmacology; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D062385:Hydroxybenzoates / Q000494:pharmacology; D007501:Iron / Q000378:metabolism; D004369:Pentetic Acid / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D013789:Thalassemia / Q000188:drug therapy
D002614:Chelating Agents; D002793:Cholic Acids; D005029:Ethylenediamines; D006877:Hydroxamic Acids; D062385:Hydroxybenzoates; D010879:Piperazines; C011813:ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid); C025920:cholylhydroxamic acid; D004758:Enterobactin; C003305:rhodotorulic acid; C009135:2,3-dihydroxybenzoic acid; D004369:Pentetic Acid; D007501:Iron; D003676:Deferoxamine